Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use
Authors
Keywords
-
Journal
DRUG SAFETY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-24
DOI
10.1007/s40264-023-01360-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of diagnostic and prognostic candidate biomarkers in drug‐induced liver injury vs. other forms of acute liver damage
- (2023) Alejandro Cueto‐Sánchez et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Nomenclature, Diagnosis and Management of Drug-induced Autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report
- (2023) Raúl J. Andrade et al. JOURNAL OF HEPATOLOGY
- Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
- (2022) Pei Jye Voon et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Value of liver biopsy in the diagnosis of drug-induced liver injury
- (2022) Jawad Ahmad et al. JOURNAL OF HEPATOLOGY
- Continued Risk of Dietary Supplements Adulterated With Approved and Unapproved Drugs: Assessment of the US Food and Drug Administration's Tainted Supplements Database 2007 Through 2021
- (2022) C. Michael White JOURNAL OF CLINICAL PHARMACOLOGY
- Comprehensive analysis and insights gained from long-term experience of the Spanish DILI registry
- (2021) Camilla Stephens et al. JOURNAL OF HEPATOLOGY
- ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
- (2021) Naga P. Chalasani et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
- (2021) Juliana Hey-Hadavi et al. DRUG SAFETY
- Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature
- (2021) Joseph William Clinton et al. DRUG SAFETY
- Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development
- (2020) Arie Regev et al. JOURNAL OF AUTOIMMUNITY
- Knowledge Mapping of Drug-Induced Liver Injury: A Scientometric Investigation (2010–2019)
- (2020) Lixin Ke et al. Frontiers in Pharmacology
- Next Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development
- (2019) Sharin E. Roth et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Drug-Induced Liver Injury — Types and Phenotypes
- (2019) Jay H. Hoofnagle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience
- (2018) John F. Marcinak et al. DRUG SAFETY
- Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort
- (2018) Rachel J. Church et al. HEPATOLOGY
- Drug-induced liver injury: a safety review
- (2018) Miren García-Cortés et al. Expert Opinion On Drug Safety
- Drug-Induced Liver Injury: Highlights of the Recent Literature
- (2018) Mark Real et al. DRUG SAFETY
- Drug-induced liver injury: recent advances in diagnosis and risk assessment
- (2017) Gerd A Kullak-Ublick et al. GUT
- Drug rechallenge following drug-induced liver injury
- (2017) Christine M. Hunt et al. HEPATOLOGY
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
- (2016) Igho J. Onakpoya et al. BMC Medicine
- Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
- (2015) Paul B. Watkins et al. DRUG SAFETY
- Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study
- (2015) Naga Chalasani et al. GASTROENTEROLOGY
- RUCAM in Drug and Herb Induced Liver Injury: The Update
- (2015) Gaby Danan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review
- (2015) Jonathan G. Stine et al. Expert Review of Gastroenterology & Hepatology
- Methodology to Assess Clinical Liver Safety Data
- (2014) Michael Merz et al. DRUG SAFETY
- Liver Safety Assessment: Required Data Elements and Best Practices for Data Collection and Standardization in Clinical Trials
- (2014) Mark I. Avigan et al. DRUG SAFETY
- Causality Assessment for Suspected DILI During Clinical Phases of Drug Development
- (2014) Arie Regev et al. DRUG SAFETY
- Liver Safety Assessment in Special Populations (Hepatitis B, C, and Oncology Trials)
- (2014) Gerd A. Kullak-Ublick et al. DRUG SAFETY
- Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury
- (2014) Mercedes Robles–Diaz et al. GASTROENTEROLOGY
- Idiosyncratic Drug-Induced Liver Injury Is Associated With Substantial Morbidity and Mortality Within 6 Months From Onset
- (2014) Robert J. Fontana et al. GASTROENTEROLOGY
- How to Avoid Being Surprised by Hepatotoxicity at the Final Stages of Drug Development and Approval
- (2013) Arie Regev Clinics in Liver Disease
- Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland
- (2013) Einar S. Björnsson et al. GASTROENTEROLOGY
- A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data
- (2013) Daniel Parks et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Why the threshold criteria should not be modified for detection of possibly serious drug-induced hepatotoxicity in special groups of trial subjects
- (2013) John R. Senior PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- A Prospective Nationwide Study of Drug-Induced Liver Injury in Korea
- (2012) Ki Tae Suk et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Validation of Multivariate Outlier Detection Analyses Used to Identify Potential Drug-Induced Liver Injury in Clinical Trial Populations
- (2012) Xiwu Lin et al. DRUG SAFETY
- High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury
- (2012) Minjun Chen et al. HEPATOLOGY
- Principles of Conservative Prescribing
- (2011) Gordon D. Schiff ARCHIVES OF INTERNAL MEDICINE
- Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
- (2011) G P Aithal et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshop
- (2010) Robert J. Fontana et al. HEPATOLOGY
- Drug-Induced Liver Injury Network (DILIN) Prospective Study
- (2009) Robert J. Fontana et al. DRUG SAFETY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started